Understanding different types of multiple myeloma precursor conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to differentiate between progressive and stable precursor conditions of multiple myeloma, specifically focusing on smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). The study will utilize established clinical diagnostic criteria and laboratory tests to confirm diagnoses and assess the biological and clinical characteristics of these conditions. By analyzing these distinct entities, the research seeks to enhance understanding of their progression and stability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosis of MGUS and SMM will be made in accordance with the clinical diagnostic criteria set forth by the 2014 International Myeloma Working Group (IMWG) Revised Criteria.2
2. The diagnoses will be confirmed by either serum/urine protein electrophoresis, immunofixation and light-chain assays; or immunohistochemistry analyses of the bone marrow biopsy, or a combination of these tests.
3. Age greater than or equal to 18 years.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
5. The patient must be competent to sign an informed consent form.

Exclusion Criteria:

1. A diagnosis of MM as defined as any patient with detectable M-protein in blood and/or urine, monoclonal plasma cells in the bone marrow, and evidence of end-organ damage based on the Calcium Elevation, Renal Failure, Anemia, and Bone Disease (CRAB) criteria and/or myeloma-defining events.

   * Patients who have received previous therapy for MM.
   * Patients with known plasma cell or related lymphoid (e.g. lymphoplasmacytic lymphoma, Amyloid Light chain (AL) amyloidosis)
2. Confirmation of pathological diagnosis is required either from the initial pathology review report or review from the UM/SCCC Hematopathologist in accordance with the clinical diagnostic criteria set forth by the International Myeloma Working Group (IMWG) or World Health Organization (WHO). Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the patient during sampling required for routine patient care or required testing on a University of Miami (UM) /Sylvester Comprehensive Cancer Center (SCCC) research protocol will be used for diagnosis.
3. Active symptomatic major organ disorder that would increase the risk of biopsy or other procedure, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.

   * Active concomitant medical or psychological illnesses that may increase the risk to the patient or inability to obtain informed consent, at the discretion of the Principal Investigator.
   * Pregnant or breast-feeding women will not be eligible for any aspect of this protocol.
   * Prisoners will be excluded.

Where it's running

• University of Miami Hospitals
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Carl Landgren, MD — University of Miami
• Study coordinator: Carl Landgren, MD
• Email: col15@miami.edu
• Phone: 3052436578

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prolonged overnight fasting combined with a Mediterranean-style diet for people with multiple myeloma or precursor conditions

  This program will test whether longer overnight fasting paired with a Mediterranean-style eating plan is doable for adults with MGUS, smoldering myeloma, or newly diagnosed multiple myeloma who are starting treatment.

  Recruiting University of Miami · Miami, Florida · NCT07446777

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

• Combining JNJ-79635322 with Daratumumab or Pomalidomide for Multiple Myeloma Treatment

  This study is testing a new drug called JNJ-79635322 combined with either daratumumab or pomalidomide to see how safe and effective it is for people with multiple myeloma.

  Recruiting at 16 sites Phase 1 Janssen Research & Development, LLC · Denver, Colorado and 15 other locations · NCT06768489

• Network for early diagnosis and management of AL amyloidosis in Italy

  This study is trying to set up a network in Italy to help doctors find AL amyloidosis earlier in patients who are at risk, so they can get treatment sooner and improve their health.

  Recruiting at 4 sites Fondazione IRCCS Policlinico San Matteo di Pavia · Bari and 3 other locations · NCT06383143

• Collection and analysis of biological samples from patients with multiple myeloma and related conditions

  This study is collecting and storing blood samples from patients with multiple myeloma and similar conditions to help researchers learn more about these diseases and improve treatments.

  Recruiting at 41 sites European Myeloma Network B.V. · Melbourne and 40 other locations · NCT06237803

• Exploring the effects of a plant-based diet and supplements on smoldering multiple myeloma

  This study is testing whether a plant-based diet and certain supplements can change butyrate levels in the stool of people with smoldering multiple myeloma.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06055894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.